biostudies-literatureJia PBeijing Key Clinical Specialty for Laboratory Medicine - Excellent ProjectNational Natural Science Foundation of ChinaNational Key Research and Development Program of China234https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526345biostudies-literatureUnknown22(1)<h4>Background</h4>Data on antibiotic resistance is essential to adapt treatment strategies against the rapidly changing reality of antimicrobial resistance.<h4>Objective</h4>To study the in vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and Gram-negative bacteria collected from China in the year 2018.<h4>Methods</h4>A total of 2301 clinical isolates were collected from 17 medical center laboratories in China, which participated in the ATLAS program in 2018. Antimicrobial susceptibilities were determined by the broth microdilution method at a central laboratory. Clinical and Laboratory Standards Institute (CLSI) breakpoints were used to interpret the results except for tigecycline, for which the US Food and Drug Administration (FDA) breakpoint wBMC microbiologyIn vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.PMC9526345ZK201000820723182021YFC2301002, 2021YFC2301000Jia PZhu YZhang HCheng BYang QGuo PXu YfalseIn vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.<h4>Background</h4>Data on antibiotic resistance is essential to adapt treatment strategies against the rapidly changing reality of antimicrobial resistance.<h4>Objective</h4>To study the in vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and Gram-negative bacteria collected from China in the year 2018.<h4>Methods</h4>A total of 2301 clinical isolates were collected from 17 medical center laboratories in China, which participated in the ATLAS program in 2018. Antimicrobial susceptibilities were determined by the broth microdilution method at a central laboratory. Clinical and Laboratory Standards Institute (CLSI) breakpoints were used to interpret the results except for tigecycline, for which the US Food and Drug Administration (FDA) breakpoint w2022-01-01T00:00:00Z2022 Oct2025-04-26T12:04:44.924Z2025-02-19T00:23:37.798ZS-EPMC95263453618289510.1186/s12866-022-02644-5